COMPARING HIFU HEMIABLATION TO ROBOTIC RADICAL PROSTATECTOMY IN THE MANAGEMENT OF UNILATERAL PROSTATE CANCER: A MATCHED PAIR ANALYSIS

Simone Alabisini, Fouad Aoun, Simon Bellucci, Ibrahim Biaou, Ksenija Limani, Eric Hawaux, Alexandre Peltier and Roland van Velthoven

1Urology Department, Jules Bordet Institute, Université libre de Bruxelles, Brussels, Belgium

Corresponding Author:
Simone Albrisini
Department of Urology
Jules Bordet Institute
Université Libre de Bruxelles
Boulevard de Waterloo 121
Brussels, Belgium
Tel. +32488975205
Fax. +32025413176
albrisini.simone@gmail.com

Wordcount
Abstract: 351
Manuscript: 2138

Keywords: HIFU, prostate cancer, robotic, unilateral.
ABSTRACT

Introduction: Although still experimental, focal treatment is being increasingly implemented in the management of prostate cancer (PCa). Aim of the current study was to compare functional and oncologic outcomes of High Intensity Focal Ultrasound (HIFU) hemiablation of the prostate to robotic-assisted laparoscopic prostatectomy (RALP) in the management of unilateral prostate cancer.

Materials: 55 men with unilateral, clinically localized PCa underwent HIFU hemiablation of the affected prostatic lobe between 2007 and 2015. All patients were diagnosed with unilateral disease on the basis on full concordance between multiparametric MRI and MRI-guided biopsies. These patients were matched 1:1 with patients who underwent RALP for PCa in which pT2a-b disease (unilateral) was found on final pathologic analysis. Matching criteria were Gleason score, PSA and cT stage. Treatment failure was defined as the need for salvage external beam radiotherapy or systemic androgen deprivation therapy (ADT) due to disease progression. Kaplan Meier curves and log-rank tests were constructed to assess differences in salvage treatment free survival across surgical techniques.

Results: Matching was successful with no significant differences across the two groups, although men treated with HIFU were older (p<0.001). Median follow-up was 36mo (IQR 16-56). HIFU was associated to better and faster recovery of continence, with most men (82%) showing no signs of urinary incontinence even right after surgery. Moreover, the risk of de novo erectile dysfunction was significantly lower after focal HIFU. No significant difference was found in the need for salvage EBRT or ADT across the two surgical approaches: 7/55 men underwent salvage therapy in the HIFU vs 6/55 in the RALP group (p=0.76). Nonetheless, 7 more patients in the HIFU arm required a complementary treatment on the contralateral lobe during follow-up, after developing a contralateral PCa. No patient died of PCa on follow-up, while 6 men died of other causes (5 HIFU vs 1 RALP, p=0.11).

Conclusion: In this matched pair analysis, HIFU hemiablation was comparable to RALP in controlling localized, unilateral PCa, with no significant differences in the need for salvage therapies. HIFU was also associated to significantly better functional outcomes. Accurate patient selection remains vital and larger prospective trials are needed to confirm our findings.
INTRODUCTION

Prostate cancer (PCa) is a major health concern worldwide, being the second most common neoplasm and sixth cause of cancer-related death in the world [1]. Radical prostatectomy, today mainly performed via a robotic-assisted approach (RALP), is a mainstay in the local control of disease. Nonetheless, the procedure is associated to significant morbidity and decline in quality of life due to continence and erectile deterioration after surgery [2]. In the effort to reduce such post-operative burden, pioneers have begun to explore the feasibility of focal therapy in selected PCa patients [3–5]: although PCa is mainly multifocal, investigators have attempted to treat the so-called “index” lesion, which is considered the major determinant in the future pathologic evolution of the disease [6]. Among the energy sources used for focal therapy, High Intensity Focal Ultrasound (HIFU) emerged as a valid minimally invasive therapy for selected patients [7], and recent studies have reported encouraging results for focal therapy delivered with HIFU [4,8,9]. With increasing specificity of preoperative characterization of PCa, thanks to multiparametric MRI and MRI-guided targeted biopsies, patient selection is becoming increasingly precise, allowing optimal selection of patients for such a focal approach.

In our department we began performing HIFU hemi ablation of the prostate 9 years ago [9], in patients with unilateral disease, proven by full correspondence between multiparametric MRI and MRI-guided targeted biopsies [10]. In the same years we were also performing RALP for patients with low and intermediate risk PCa, of which some also harbored unilateral disease as demonstrated by final pathologic analysis. Aim of the current study was to compare functional and oncologic outcomes of HIFU hemiablation of the prostate to RALP in the management of unilateral PCa.
Patients and Methods

After institutional review board approval, we retrospectively analyzed patients undergoing HIFU prostatic hemiablation for unilateral disease and patients who underwent RALP for pT2a-pT2b (unilateral) prostate cancer between 2007 and 2015.

For HIFU hemiablation, patients were selected if the positive biopsy pattern was in complete concordance with the prostate cancer lesions identified by MRI with precise loci matching on multiparametric approach. We included men with localized prostate cancer (≤cT2), a PSA <15 mcg/ml, a life expectancy of at least 5 years, and a prostate volume <40 cm³. We excluded patients who had extra-prostatic extension on multiparametric MRI, suspected regional lymph nodes or distant metastases on cross-sectional imaging or bone scan, and/or previous HIFU or radiation therapy to the prostate. All patients underwent hemiablation using HIFU delivered by the Ablatherm integrated imaging system (EDAP-TMS, Vaulx-en-Velin, France), performed by a single surgeon (RVV) with a high level of experience in whole-gland HIFU. HIFU hemiablation was defined as ablation of one lobe of the prostate and not just the index lesion because of device technical limitations. HIFU energy was delivered only to the hemi prostate gland, with no treatment of the ipsilateral neurovascular bundle within the technical feasibility of the approach.

Matching

Patients treated by HIFU prostatic hemiablation were matched 1:1 by propensity score analysis with patients undergoing RALP in the same years, in which unilateral PCA was detected on final pathologic report (pT2a-2b, unilateral disease). RALP was performed by 3 expert surgeons (RVV, AP, EH), all using the same surgical technique. A bilateral nerve sparing approach was performed in all cases. Urinary catheter was usually retrieved at day 5 post-operatively, after a retrograde cystography showing no leakage. The matching procedure was blinded to the outcome, guaranteeing the sorting of patients according to the matching
parameters without bias in their outcomes. Matching criteria were, in order: Gleason score, preoperative PSA and cT stage (cT1c vs cT2). To confirm an appropriate matching, the absence of significant clinical and pathologic differences between the two cohorts of patients treated was assessed using Wilcoxon Rank-sum or $\chi^2$-test, as appropriate.

**Functional Follow-up**

Urinary functional outcomes and erectile function were reported using patient-reported rates. Continence was considered in a categorical fashion as 0 vs $\geq$1pad. Patients were considered potent if erections, with or without iPDE5, were sufficient for intercourse.

**Oncologic Follow-up**

Given the inherent difference across the two surgical approaches (organ-sparing vs radical extirpation), comparison of biochemical recurrence rates using PSA is inadequate. Moreover, there is currently no accepted definition for disease control following HIFU [11,12]. We therefore decided to test difference in treatment failures, identified as the need for local salvage therapy (radiotherapy of surgery), hormonotherapy or metastases.

**HIFU**

Given the presence of an untreated half-prostate, an individual PSA nadir was identified in each patient. Biochemical recurrence according to Phoenix criteria (Nadir+2 ng/ml) [13] was used as a threshold to offer a new set of bilateral biopsies. Treatment failure was defined as positive biopsy of the treated area independently of the percentage of core involvement or if salvage radiation or hormonal therapy was needed during follow-up. Contralateral positive biopsy was not considered as a clinical failure but as a metachronous development of a contralateral disease and was treated by a secondary contralateral hemiablation according to our protocol.

RALP
Biochemical recurrence was defined by a PSA levels > 0.2 ng/ml and subsequently rise [14]. The date of the first PSA ≥0.2 ng/ml was used to define biochemical recurrence. Salvage radiotherapy or hormonotherapy were offered according to PSA doubling time, pathologic Gleason score and final pathologic report.

Kaplan Meier curves and log-rank tests were performed to analyze the influence of the surgical approach on salvage treatment free survival. Statistical significance was considered for p≤0.05. Analyses were performed using STATA version 11.1 (StataCorp, TX).

RESULTS

55 patients treated by HIFU hemiablation were identified and included in the study. These were matched 1:1 to to 55 men who had undergone RALP with pT2a-2b stage in the same years. Matching was successful with no significant differences across the two groups (table 1), although men treated with HIFU were older (p<0.001).

Concerning early post-operative complications, these were detected in 8/55 (15%) in the HIFU group and 11/55 (20%) in the RALP group (p=0.71). These events were mainly Clavien I complications, as prolonged acute urinary retention after HIFU and anastomotic leakage requiring extra catheter days in the RALP group. All Clavien II complications were urinary tract infections. One patient developed malignant hypertension requiring intensive care in the RALP group. Length of stay was 4 days (IQR 3-5) in the HIFU group and 7 (IQR 7-8) in the RALP group (p<0.001). Of note, our patients are allowed to leave the ward only after all catheters and drains are withdrawn.

Median follow-up was 36mo (IQR 16-56). Concerning functional outcomes (table 2), HIFU was associated to better and faster recovery of continence, with most men (82%) showing no signs of urinary incontinence (0 pads) even just after surgery. This rate was significantly more elevated compared to patients undergoing RALP, in which 40% had 0 pads
at 1 month control (p<0.001). Moreover, the risk of de novo erectile dysfunction was significantly lower after focal HIFU. Indeed, a higher rate of patients in the RALP group presented de novo, persistent erectile dysfunction after surgery (44% vs 20%, p=0.03). It must be highlighted that patients in the HIFU arm were also older, thus at increased risk of post-operative erectile dysfunction [15].

Specific biochemical outcomes of HIFU hemi ablation have been previously published [9]. When analyzing oncologic outcomes, we did not observe a significant difference in terms of salvage therapy free survival across the two groups (Figure 1). In fact, 7/55 patients in the HIFU arm vs 6/55 patients in the RALP arm required salvage EBRT, ADT or both during follow up (p=0.76), with a non significant difference in time to salvage therapy (Table 3). In the HIFU arm, 2/7 patients had ipsilateral recurrence and 5/7 had bilateral disease: in particular, two patient presented gleason 6 (3+3) recurrence, two patients had gleason 7 (3+4), two had gleason 7 (4+3) and one had a gleason 8 (4+4) recurrence. Nonetheless, 7 (13%) more patients in the HIFU arm required a complementary HIFU treatment on the contralateral lobe during follow-up, after developing a contralateral PCa. No patient died of PCa on follow-up, while 6 men died of other causes (5 HIFU vs 1 RALP, p=0.11).

DISCUSSION

Urology is a dynamic surgical specialty, with revolutionary changes which are constantly occurring. Focal therapy for PCa, which is still considered experimental [16], is a promising approach for localized prostate cancer, as new genetic and clinical data are suggesting that the outcome of the disease is mainly driven by the index lesion [6]. The focalized treatment of the index lesion could therefore obtain similar oncologic outcomes to
whole gland therapy, though reducing morbidity, particularly concerning continence and sexual potency [17].

In this retrospective matched-pair analysis, we compared functional and oncologic results of two diametrically different approaches to unilateral prostate cancer. On the one hand we offered radical treatment via RALP: indeed these patients had worse functional outcomes, with a slower recuperation of continence and a worse recovery of sexual function. On the other hand patient undergoing focal therapy achieved better functional results, and this is not surprising given the inherent tissue sparing approach of focal therapy. Of note, median age in the focal therapy arm was 73 years, and it is known that age is the most important risk factor for urinary incontinence following radical treatment of PCa [18,19]. As such, an 82% full continence rate at 1 month after surgery, in such an “old” group of men, is not only better than our RALP results, but is indeed very appealing especially for older men in whom surgery may determine major aggravation of continence status [18,19]. A similar consideration can be made for our potency results: clearly, a tissue sparing approach determined a much lower negative impact of erectile function, especially in older men with a baseline worse erectile function [18,20]. Concerning post-operative complications, these are low across both techniques, and are mainly represented by the need of prolonged urinary drainage or urinary tract infections, both classified as minor complications [21].

On the other comparing oncologic outcomes of a radical versus a focal therapy can be tricky. Indeed, in a tissue sparing procedure as HIFU hemiablation, healthy prostatic glands (which physiologically produce PSA) are by definition left behind. As such, the definition of biochemical recurrence is still a matter of debate across experts in the field and no consensus exists [5]. Frequently, researchers have used the Phoenix criteria used after radiotherapy for PCa [13]: yet, these criteria are suboptimal in focal therapy. In our center, we use Phoenix criteria to prompt diagnostic work-up, including multiparametric MRI and prostate biopsies.
In the RALP group, BCR was experienced by 6/55 patients (11%), as similar to other low and intermediate risk series [16,22,23]. Similarly, 7/55 patients in the HIFU arm required salvage treatment as a consequence of the failure of HIFU hemiablation to control PCa. Thus, it appears that the oncologic control of the index lesion determined by HIFU hemiablation was similar to that obtained by RALP, when considering treatment failure (i.e. the need for salvage radio or hormone therapy). These results are encouraging, although they must be handled with care. A great difference across the two arms of our study is that in the RALP group, unilateral disease is determined on whole-mount pathologic examination, while in the HIFU such “unilateral status” is defined by MRI and targeted biopsies. As such, while in the RALP group we are sure that all patients truly harboured only unilateral disease, in the HIFU groups there might have been patients with bilateral disease, erroneously diagnosed with unilateral PCa, contributing to the number of men who failed treatment and required salvage therapy. Clearly, adequate patient selection and perfect preoperative diagnosis are vital when performing focal therapy. As such, it may be possible that part of the disease progressions observed in the HIFU arm (requiring salvage treatment) are due to inaccurate diagnosis, rather than treatment failure.

When leaving a prostatic lobe untreated, patients remain at risk of developing contralateral PCa [5]. This is an inherent aspect of focal therapy, which is normally discussed with the patient prior to surgery. In fact, it can be considered that active surveillance and focal therapy are two complementary strategies of the same therapeutic pathway [24]. Moreover, PCa can be already present in the contralateral, untreated lobe as a consequence of a missed diagnosis on biopsy. In our center, where mp-MRI is incorporated to MRI-guided fusion targeted biopsies [10], this is especially true in the case of OMS 2016 Grade I PCa (Gleason 6), which can be underdiagnosed on multiparametric MRI [25]. In the current study, 7/55 (13%) extra patients required secondary HIFU hemiablation of the contralateral lobe, due to
the development of contralateral PCa, which is generally considered acceptable by experts of focal therapy [5]. These patients may be considered a failure of our approach and must be kept in mind when counselling men on PCa treatment. Although the consequences of contralateral recurrence are usually minor compared to salvage therapy, its exclusion from failures in the current study may have induced a bias with undue advantage for HIFU hemiablation over RALP, and as such represents a limitation of the study.

Our study is not devoid of limitations. First, comparing focal therapy to radical surgery may seem like comparing apples and pears; our results must be interpreted with caution. Moreover, the follow-up is limited and insufficient to draw definite conclusions on oncologic control obtained by our focal therapy. Finally, the study is retrospective in nature and the number of patients is limited.

CONCLUSIONS

In this retrospective matched-pair analysis, HIFU hemiablation of the prostate was comparable to RALP in controlling localized, unilateral PCa, with no significant differences in the need for salvage therapies. However, patients undergoing focal treatment of PCa remain at risk of contralateral PCa, which required a contralateral hemiablation in 7/55 (13%) of our patients. HIFU hemiablation of the prostate was also associated to significantly better urinary continence and erectile potency recovery. Accurate patient selection remains vital and larger prospective trials are needed to confirm our findings.

REFERENCES


ABBREVIATIONS

PCa: Prostate Cancer
HIFU: High Intensity Focal Ultrasound
RALP: Robotic assisted laparoscopic prostatectomy
ADT: Androgen deprivation therapy
Table 2. Peroperative and post-operative outcomes

<table>
<thead>
<tr>
<th></th>
<th>Focal HIFU</th>
<th>RALP</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital stay (days)</td>
<td>4 (3-5)</td>
<td>7 (7-8)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td></td>
<td>4±1</td>
<td>8±2</td>
<td></td>
</tr>
<tr>
<td>Early complications</td>
<td>8 (15%)</td>
<td>11 (20%)</td>
<td>0.45°</td>
</tr>
<tr>
<td>Grade early complications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clavien I</td>
<td>7</td>
<td>7</td>
<td>0.71°</td>
</tr>
<tr>
<td>ClavienII</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Clavien III</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Clavien IV</td>
<td>0</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Continence (0 pads)</td>
<td></td>
<td></td>
<td>&lt;0.001°</td>
</tr>
<tr>
<td>1mo</td>
<td>82% (45)</td>
<td>40% (22)</td>
<td></td>
</tr>
<tr>
<td>3mo</td>
<td>87.5% (48)</td>
<td>55% (30)</td>
<td></td>
</tr>
<tr>
<td>6mo</td>
<td>89.5% (49)</td>
<td>71% (39)</td>
<td></td>
</tr>
<tr>
<td>12 mo</td>
<td>94.5% (52)</td>
<td>87% (48)</td>
<td></td>
</tr>
<tr>
<td>24 mo</td>
<td>94.5% (52)</td>
<td>91% (50)</td>
<td></td>
</tr>
<tr>
<td>Incontinent</td>
<td>5.5% (3)</td>
<td>9% (5)</td>
<td></td>
</tr>
<tr>
<td>Erectile Dysfunction</td>
<td></td>
<td></td>
<td>0.03°</td>
</tr>
<tr>
<td>Preop potent and active</td>
<td>30</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>Potent at 1mo</td>
<td>80% (24)</td>
<td>15% (7)</td>
<td></td>
</tr>
<tr>
<td>Potent at 12mo</td>
<td>80% (24)</td>
<td>38% (18)</td>
<td></td>
</tr>
<tr>
<td>Potent at 24mo</td>
<td>80% (24)</td>
<td>56% (27)</td>
<td></td>
</tr>
<tr>
<td>De Novo persistent ED</td>
<td>20% (6)</td>
<td>44% (21)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Focal HIFU</td>
<td>RALP</td>
<td>p-value $^\circ$</td>
</tr>
<tr>
<td>--------------------------</td>
<td>------------</td>
<td>------</td>
<td>-----------------</td>
</tr>
<tr>
<td><strong>Salvage therapy</strong></td>
<td>7/55</td>
<td>6/55</td>
<td>0.76</td>
</tr>
<tr>
<td><strong>Treatment description</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBRT</td>
<td>1</td>
<td>3</td>
<td>0.76</td>
</tr>
<tr>
<td>EBRT + ADT</td>
<td>2</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>ADT</td>
<td>3</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Salvage prostatectomy</td>
<td>1</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>Time to salvage (mo)</strong></td>
<td>23 (12-61)</td>
<td>34 (15-50)</td>
<td>0.81</td>
</tr>
</tbody>
</table>

EBRT: external beam radiation therapy; ADT: Androgen deprivation therapy

$^\circ \chi^2$